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Abstract
Acinetobacter baumannii is an increasingly common cause of infection in intensive-care units throughout the world, and the occurrence
of multiresistant A. baumannii is increasing. The aim of this study was to determine whether a highly puriﬁed polyphenol, (–)-epigallo-
catechin-3-gallate (EGCG), from green tea (Camellia sinesis), had antimicrobial effects against multiresistant clinical isolates of A. baumannii.
Standard microplate assays were performed to determine the MIC of EGCG for 21 clinical isolates of A. baumannii. MICs ranged from
0.078 to 0.625 mg/mL, with MIC50 and MIC90 of 0.312 mg/mL and 0.625 mg/mL, respectively. All of the isolates of A. baumannii tested
were killed by EGCG. In time-kill assays, EGCG resulted in a 3-log reduction in CFU/mL of A. baumannii after 5 h of incubation with
the polyphenol. Synergy between the commonly used topical agent 5% mafenide acetate (Sulfamylon) and EGCG was noted for one clin-
ical isolate, and partial synergy was noted for three other isolates. These ﬁndings demonstrate that EGCG is an effective bactericidal
agent against antibiotic-resistant A. baumannii clinical strains in laboratory settings. EGCG has previously been shown to be safe, and
therefore may be an attractive addition for the treatment of cutaneous A. baumannii infections where high concentrations of the drug
can be applied to the wound surface.
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Introduction
Acinetobacter baumannii strains are increasingly common nos-
ocomial pathogens in intensive-care units (ICUs) worldwide.
Furthermore, infections with multiresistant strains of
A. baumannii are becoming more prevalent in ICUs and in
injured soldiers returning from Iraq and Afghanistan [1,2].
Acinetobacter spp. are aerobic Gram-negative cocobacilli that
are generally found on the skin [3]. Typically, hospital infec-
tions with Acinetobacter spp. occur in immunosuppressed
patients, such as those with burns, and include urinary,
bloodstream, pulmonary and surgical site infections. Risk
factors have been reported, including mechanical ventilation,
use of broad-spectrum antibiotics, and catheterization.
A multiresistant A. baumannii infection can make treatment
problematic. Some isolates of Acinetobacter are resistant,
through a variety of mechanisms, to most major antibiotic
classes that are used for Gram-negative infections [4]. For
highly antibiotic-resistant strains of A. baumannii, one of the
remaining antibiotics with efﬁcacy is colistin (polymyxin E).
However, the reported toxicity (primarily nephrotoxicity
and neurotoxicity) of the polymyxins has discouraged their
frequent use. More troubling is the recent report of the
development of colistin resistance in A. baumannii [5]. It is of
signiﬁcant clinical interest to identify alternative compounds
that are non-toxic and efﬁcacious against drug-resistant
Acinetobacter infections. Burn patients present a particular
need for antimicrobial therapy, because they are susceptible
to burn site infections, which can become invasive. Such
patients receive both systemic and topical antimicrobial
treatments; the use of topical agents allows high concentra-
tions of the agent to be applied directly to the site where
the microorganisms are located. Therefore, the antimicrobial
effects of (–)-epigallocatechin-3-gallate (EGCG) against a
number of clinical isolates of A. baumannii were examined.
The safety of this compound, its low cost and its effects on
other microbes may make EGCG an attractive addition for
topical treatment of infections.
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EGCG is the major polyphenol found in green tea
(Camellia sinesis). The related polyphenols: EGC (epigallocate-
chin), ECG (epicatechin gallate), EC (epicatechin), GC
(gallocatechin), and C (catechin) are also present.
This polyphenol has been widely reported to have antioxi-
dant and anticancer effects in certain systems as well as pro-
moting cardiovascular health [6,7]. Notably, EGCG and
related catechins have recently been demonstrated to be
effective as antimicrobial compounds against a variety of
pathogenic and non-pathogenic microorganisms, such as
Bacillus cereus [8], Gram-negative rods [9], Mycobacterium
tuberculosis [10], pathogenic yeasts [11], and Helicobacter
pylori [12]. In light of EGCG’s effects on various microbial
strains, the potential use of EGCG in clinical settings,
particularly against antibiotic-resistant A. baumannii strains, is
of interest, especially as EGCG and related polyphenols are
reported to have little toxicity, even at high concentrations
[13,14].
The purpose of this study was to determine the MICs of
highly puriﬁed EGCG against a panel of A. baumannii clinical
isolates. These isolates were collected from paediatric burn
patients over a 10-year period, and have varying degrees of
antibiotic resistance. Bacterial killing over time by EGCG and
the effect of combined treatment with EGCG and the topical
antimicrobial mafenide acetate (Sulfamylon) were also
examined.
Materials and Methods
EGCG was provided by S. H. Hyon (Institute for Frontier
Medical Sciences, Kyoto University, Japan), with purity in
excess of 90%. Commercially prepared EGCG, EGC and
hybridoma-tested dimethylsulphoxide (DMSO) were pur-
chased from Sigma (St Louis, MO, USA). For antimicrobial
assays, EGCG was dissolved in 100% DMSO. The ﬁnal con-
centration of DMSO was 1% in all assays. Additionally, 1%
DMSO-only samples were included in all assays. Mafenide
acetate (Sulfamylon) (Bertek Pharmaceuticals, Research Tri-
angle Park, NC, USA) was kindly provided by the hospital
pharmacy (Shriners Hospitals for Children). The MICs for
each clinical isolate of A. baumannii were determined, in trip-
licate, using standard 96-well round-bottomed microtitre
plates according to standard (CLSI) clinical guidelines [15].
Chequerboard synergy microdilution testing and time-kill
assays were performed according to the appropriate sections
in the ASM clinical microbiology procedures handbook [16].
Synergy was deﬁned as a fractional inhibitory concentration
of 0.5 or less, and partial synergy as a fractional inhibitory
concentration between 0.5 and 1.0. For time-kill assays, the
limit of detection was 10 CFU/mL. Clinical isolates were
identiﬁed by Microscan Walkaway 40SI (Dade Behring, Sacra-
mento, CA, USA), with absence of haemolysis on blood agar
for speciation as A. baumanni. Antibiograms were determined
with a Microscan Walkaway 40SI (Dade Behring) according
to standard practice.
Results
A panel of 21 A. baumannii isolates collected from paediatric
burn patients at our hospital over a 10-year period (1996–
2006) was used for testing. For each isolate, antibiograms
were determined for a panel of common Gram-negative anti-
biotics (Fig. 1). A signiﬁcant number of isolates had extensive
resistance to antibiotics. Indeed, isolate 1 (Fig. 1) was resis-
tant to all antibiotics used in the panel.
EGCG caused inhibition of growth of A. baumannii on
Mueller–Hinton assay plates. As seen in Fig. 2, the highest
dose of EGCG used (2.5 mg/mL) produced a large clearing
(c. 7 mm) against a highly drug-resistant strain of A. baumannii
(isolate 13). Reduced doses of EGCG resulted in progres-
sively smaller clearings around the wells (data not shown).
EGCG produced clearings against all tested clinical isolates of
A. baumannii (data not shown). In Fig. 3, the MIC (bars) and
the number of antimicrobial agents to which the isolate is
resistant (line) are shown. The MICs of commercially (Sigma)
available EGCG and EGC (data not shown) were consistent
with those recorded with puriﬁed EGCG. For the 21 isolates
tested, the MIC50 was 0.312 mg/mL and the MIC90 was
0.625 mg/mL. There was no apparent correlation between
antibiotic resistance pattern and the EGCG MIC of an isolate.
However, there appeared to be more variation in the MICs
for the highly drug-resistant strains of A. baumannii. Highly
drug-resistant isolates were found throughout the collection
period; however, we did note that the more recent isolates
(collected in 2004–2006) (data not shown) had a greater
degree of antibiotic resistance.
Following the ﬁnding that EGCG killed multiresistant iso-
lates of A. baumannii, EGCG was tested using 5% mafenide
acetate, which is the most commonly used topical agent at
this paediatric burn-care facility. This was to determine
whether there was synergy, partial synergy, indifference or
antagonism when the two compounds were used in combina-
tion. Three highly drug-resistant isolates (isolates 1, 3, and 6)
and one antibiotic-susceptible isolate (isolate 20) were
tested using chequerboard assays. Isolate 6 demonstrated
synergy between EGCG and mafenide acetate at concentra-
tions of 0.039 lg/lL and 0.625%, respectively. For the other
three isolates tested, partial synergy was observed between
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EGCG and mafenide acetate. As a further test of the antibacte-
rial properties of EGCG, time-kill assays were performed
(Fig. 4) on two drug-resistant isolates (1 and 6). For both iso-
lates, there was a c. 3-log reduction in CFU/mL after 5 h of
incubation with EGCG. Gram stains of the well contents from
the time-kill assay were performed, and only in the DMSO
control were intact bacteria apparent. For the remaining time-
points, no intact A. baumannii organisms were observed in
multiple ﬁelds.
DISCUSSION
The data presented demonstrate that highly puriﬁed EGCG
from green tea leaves is effective in killing multiresistant clini-
cal isolates of A. baumannii. The MICs for EGCG (Fig. 3) and
commercially available EGCG and EGC preparations (data
not shown) were roughly equivalent in their ability to kill
A. baumannii. In time-kill assays for two isolates (1 and 6),
EGCG was bactericidal after approximately 5 h of exposure.
For one isolate there was synergy between mafenide acetate
(Sulfamylon) and EGCG, and there was partial synergy for
the other isolates tested.
We, and others, have tested EGCG and EGC against
other pathogenic bacteria (e.g. Pseudomonas aeruginosa and
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FIG. 1. Antibiograms of 21 clinical isolates of Acinetobacter baumannii from paediatric burn patients. Resistance is represented by black squares,
intermediate effects by white squares, and sensitivity to the antibiotic by grey squares. SAM, ampicillin–sulbactam; AMK, amikacin; ATM, aztreo-
nam; CRO, ceftriaxone; CAZ, ceftazidime; CTX, cefotaxime; CIP, ciproﬂoxacin; FEP, cefepime; GEN, gentamicin; IPM, imipenem; BVX, benoﬂox-
acin; PIP, piperacillin; SXT, trimethoprim–sulphamethoxazole; TET, tetracycline; TIM, ticarcillin–K clavulanic acid; TOB, tobramycin. Isolates were
sorted so that the isolates with resistance to the greatest number of antibiotics are listed ﬁrst.
FIG. 2. Inhibition of Acinetobacter baumannii growth by (–)-epigallo-
catechin-3-gallate (EGCG). A. baumannii isolate 13 was seeded on
Mueller–Hinton agar plates, and 100 lL of 2.5 mg/mL EGCG in 1%
dimethylsulphoxide (DMSO) was placed in the well (left well of ﬁg-
ure) and 1% DMSO vehicle was placed in the control well (right well
of ﬁgure). This result is typical of the effect of EGCG on the growth
of multiresistant clinical isolates of A. baumannii by well diffusion on
Mueller–Hinton agar plates. The scale bar is 1 cm in length.
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Klebsiella pneumoniae) (unpublished data). The concentration
of EGCG necessary to kill these isolates was comparable to
the quantity needed to kill A. baumannii. However, unlike the
A. baumannii isolates, some of these other strains were
completely resistant to the effects of EGCG at the doses
tested. The most potent effect observed was that of EGCG
against methicillin-resistant Staphylococcus aureus (MRSA).
The dose of EGCG needed to kill these microbes was
ten-fold less than that needed for A. baumannii (data not
shown). These ﬁndings suggest that the cellular process that
EGCG affects in A. baumannii is conserved across isolates
and that similar mechanisms are present in other pathogenic
bacteria.
How EGCG or its related polyphenols kill bacteria has
not been completely elucidated. EGCG has been demon-
strated to damage the cell wall in a number of different
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FIG. 3. Resistance pattern of Acinetobacter
baumannii isolates and MICs. The MIC of puri-
ﬁed (–)-epigallocatechin-3-gallate (EGCG) (in
1% dimethylsulphoxide) for each clinical isolate
of A. baumannii (bars) is plotted with the num-
ber of antibiotics (line) to which each isolate
was resistant, as shown in the antibiogram
(Fig. 1). Intermediate antibiotic resistance, as
seen in Fig. 1, was considered resistant.
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FIG. 4. Time-kill assay for (–)-epigallocatechin-
3-gallate (EGCG) against two multiresistant
Acinetobacter baumannii isolates. A time-kill
assay was performed for isolates 1 and 6. Killing
was determined in vehicle (1% dimethylsulph-
oxide (DMSO)) with 1/2 · MIC, 1 · MIC and
2 · MIC for each isolate.
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Gram-negative bacteria [17,18]. Our microscopic data indi-
cated destruction of the organism following approximately
5 h of exposure. EGCG and related catechins have been
shown to reduce b-lactam resistance in MRSA [19,20]. Yam
et al. [21] suggest that EGCG’s ability to reverse methicillin
resistance is mediated by inhibition of the synthesis of the
penicillin-binding protein PBP2¢ as well as of b-lactamase
secretion. Electron microscopic studies revealed extensive
internal cell wall abnormalities in MRSA, suggesting that the
active component of EGCG selectively inhibits cell wall syn-
thesis [18]. Zhao et al. suggest that there are two mecha-
nisms that work synergistically to inhibit MRSA growth
[9,20]: binding to peptidoglycan, and blocking the activity of
penicillinase. Consistent with this is the report that EGCG
acts synergistically with penicillin to kill S. aureus [22]. How-
ever, Zhao et al. [23] suggest that the cellular location of
microbial b-lactamases may inﬂuence the degree to which
EGCG prevents microbial growth. b-Lactamases in
A. baumannii are periplasmic, as opposed to those in MRSA,
which are membrane-bound or secreted. This difference in
b-lactamase location may explain the difference in the
concentrations of EGCG needed to kill these two species.
However, the precise mechanism of EGCG inhibition of
microbial growth is still undeﬁned. EGCG and other
polyphenols can complex with proteins and polysaccharides,
and this could account for inhibition of b-lactamases and/or
other microbial proteins [24].
Data from the present study indicate that EGCG repre-
sents a potentially attractive alternative for topical treat-
ment of A. baumannii infections. Additionally, because
EGCG can potentially synergize with mafenide acetate, it
may provide an effective combination therapy. For some
A. baumannii infections, one of the only antibiotics that
remains effective is colistin. A report by Li et al. [5] dem-
onstrated the development of resistance to colistin in some
isolates of A. baumannii. Also, because of the reported
nephrotoxicity and neurotoxicity of the colistins, their use
has been curtailed.
Recently, a few reports have suggested that EGCG may
cause hepatoxicity [25,26]. However, in these cases, the
cause of the toxicity remains controversial, as the EGCG
and green tea polyphenols consumed by those affected were
taken with other constituents as herbal weight loss supple-
ments. With topical application, the distribution of EGCG to
the liver would probably be very limited. Severe burns often
destroy large areas of skin, muscle, and the associated vascu-
lature; therefore, antibiotics that are given systemically often
cannot reach therapeutic levels at the wound surface. The
impaired vasculature of the burn wound also limits penetra-
tion from the wound surface to the systemic circulation of
topically applied antibiotics. This greatly reduces any toxic
effects of high concentrations of topical antimicrobials. As
part of routine burn treatment, topical agents can be applied
at high concentrations to the burn wound site to prevent
microbial growth [27].
With the appearance of multiresistant strains of
A. baumannii in ICUs, and burn units, as well as in soldiers
returning from overseas, new treatments for such infections
are needed. Although the use of EGCG as a parenteral or
enteral agent to control A. baumannii has yet to be explored,
its use as a topical agent in a variety of situations, such as
burns, warrants further investigation.
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